DrugPatentWatch Database Preview
Details for Patent: 9,339,504
Which drugs does patent 9,339,504 protect, and when does it expire?
Patent 9,339,504 protects LAMICTAL ODT and is included in one NDA.
This patent has seventeen patent family members in twelve countries.
This patent has seventeen patent family members in twelve countries.
Summary for Patent: 9,339,504
| Title: | Orally disintegrating tablet compositions of lamotrigine |
| Abstract: | The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients. |
| Inventor(s): | Venkatesh; Gopi M. (Vandalia, OH), Vyas; Nehal H. (Yardley, PA), Gosselin; Michael (Springboro, OH), Lai; Jin-Wang (Springboro, OH) |
| Assignee: | ADARE PHARMACEUTICALS, INC. (Lawrenceville, NJ) |
| Application Number: | 14/172,962 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 9,339,504
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | LAMICTAL ODT | lamotrigine | TABLET, ORALLY DISINTEGRATING;ORAL | 022251-001 | May 8, 2009 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES | ➤ Sign Up | ||
| Glaxosmithkline Llc | LAMICTAL ODT | lamotrigine | TABLET, ORALLY DISINTEGRATING;ORAL | 022251-004 | May 8, 2009 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 9,339,504
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,840,925 | Orally disintegrating tablet compositions of lamotrigine | ➤ Sign Up |
| 7,919,115 | Orally disintegrating tablet compositions of lamotrigine | ➤ Sign Up |
| 8,647,656 | Orally disintegrating tablet compositions of lamotrigine | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Family Members for US Patent 9,339,504
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Brazil | PI0814408 | ➤ Sign Up | |||
| Canada | 2693072 | ➤ Sign Up | |||
| China | 101801192 | ➤ Sign Up | |||
| China | 104161733 | ➤ Sign Up | |||
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
